In short
A new clinical trial is exploring the potential of Mocravimod, a drug that may improve outcomes for adult patients with Acute Myeloid Leukemia (AML) who are undergoing allogeneic hematopoietic cell transplantation (HCT). This study aims to evaluate the effectiveness and safety of Mocravimod when used as an additional treatment alongside standard care and as a maintenance therapy following transplantation.
At a glance
- Study Type
- Randomized, double-blind, placebo-controlled, multi-center Phase III study
- Drug
- Mocravimod (S1PR modulator)
- Condition
- Adult Acute Myeloid Leukemia (AML)
- Treatment Groups
- 3mg Mocravimod, 1mg Mocravimod, Placebo
- Treatment Duration
- 12 months
- Primary Outcome
- Relapse-free survival (RFS)
- Secondary Outcome
- Overall survival (OS)
- Treatment Context
- Adjunctive and maintenance treatment for patients undergoing allogeneic HCT
What is MOCRAVIMOD?
MOCRAVIMOD is a new drug being studied for the treatment of Adult Acute Myeloid Leukemia (AML). AML is a type of blood cancer that affects the bone marrow, where blood cells are produced. This drug is specifically designed to help patients who are undergoing a stem cell transplantation, also known as allogeneic hematopoietic cell transplantation (HCT).
How MOCRAVIMOD Works
MOCRAVIMOD is classified as an S1PR modulator. S1PR stands for Sphingosine-1-phosphate receptor. These receptors play a crucial role in regulating the immune system and cell movement. By modulating these receptors, MOCRAVIMOD may help improve the success of stem cell transplantation and reduce the risk of cancer relapse.
Clinical Trial Overview
A large-scale clinical trial is currently underway to evaluate the effectiveness and safety of MOCRAVIMOD. This study is described as a:
- Multi-center trial: The study is being conducted at multiple hospitals or research centers.
- Randomized: Patients are randomly assigned to different treatment groups.
- Double-blinded: Neither the patients nor the doctors directly involved in their care know which treatment each patient is receiving.
- Placebo-controlled: Some patients will receive a placebo (a harmless substance with no active ingredients) instead of the actual drug.
This type of study design helps ensure that the results are reliable and not influenced by bias.
Treatment Arms
The study has three treatment groups, also called "arms":
- 3mg MOCRAVIMOD arm: Patients in this group receive 3 mg of MOCRAVIMOD orally (by mouth) once per day for 12 months.
- 1mg MOCRAVIMOD arm: Patients in this group receive 1 mg of MOCRAVIMOD orally once per day for 12 months.
- Placebo arm: Patients in this group receive a placebo orally once per day for 12 months.
The purpose of having different dosage groups is to determine the most effective and safe dose of the medication.
Expected Outcomes
The researchers are primarily interested in two main outcomes:
- Relapse-free survival (RFS): This measures how long patients live without their cancer returning after treatment.
- Overall survival (OS): This measures how long patients live overall after starting the treatment.
The study aims to compare these outcomes between patients receiving MOCRAVIMOD and those receiving the placebo.
Potential Benefits
If successful, MOCRAVIMOD could offer several benefits for AML patients undergoing stem cell transplantation:
- Improved success rates of stem cell transplantation
- Reduced risk of cancer relapse
- Increased survival time without cancer recurrence
- Potentially improved overall survival
It's important to note that these potential benefits are still being studied, and the final results of the clinical trial will provide more definitive information about the effectiveness of MOCRAVIMOD.